Efficacy of the topic RV3131A-HC3221 in the prevention of polymorphic light eruption

Efficacy of the topic RV3131A-HC3221 in the prevention of polymorphic light eruption

Hide study title
Status
Status :
Completed
Type of study
Phase II
Min. Age
18
Years old
Max. Age
64
Years old
Gender
All
Therapeutic area :
Dermatology
Disease :
Polymorphic light eruption
Study medication :
Rv313
Phase : Phase II
Start Date :
28 September 2004
End date :
14 February 2006
Study ID : V00096 CR 201
EudraCT/CTIS number : 2004-001241-14

Results

Public links :

Send by email